Table II.
Original diagnosis of primary cancer in patients with therapy-related acute myeloid leukemia
| Primary Disease, No. (%) | t-AML* N=301 |
t-AML without AHD* N=183 |
t-AML with AHD* N=118 |
P |
|---|---|---|---|---|
| Solid cancers | 204 (68) | 121 (66) | 83 (70) | 0.445 |
| Breast | 80 (27) | 61 (33) | 19 (16) | 0.001 |
| Prostate | 49 (16) | 8 (4) | 41 (35) | <0.001 |
| Sarcoma | 13 (4) | 11 (6) | 2 (2) | 0.072 |
| Head and Neck | 11 (4) | 6 (3) | 5 (4) | 0.665 |
| Colon | 11 (4) | 9 (5) | 2 (2) | 0.146 |
| Lung | 8 (3) | 5 (3) | 3 (3) | 0.920 |
| Bladder | 8 (3) | 6 (3) | 2 (2) | 0.404 |
| Other | 24 (8) | 18 (10) | 6 (5) | 0.137 |
| Hematologic malignancies | 120 (40) | 77 (42) | 43 (36) | 0.330 |
| Non-Hodgkin lymphoma | 92 (31) | 61 (33) | 31 (26) | 0.194 |
| Hodgkin lymphoma | 12 (4) | 5 (3) | 7 (6) | 0.166 |
| Multiple myeloma | 5 (2) | 3 (2) | 2 (2) | 0.971 |
| Other | 8 (3) | 4 (2) | 4 (3) | 0.526 |
Abbreviations: t-AML, therapy-related acute myeloid leukemia; AHD, antecedent history of dysplasia
*
: ≥ 3% of patients with t-AML with or without AHD were described in the table